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abstract
PURPOSE Pembrolizumab has previously shown antitumor activity against programmed death ligand 1 (PD-L1)–
positive metastatic castration-resistant prostate cancer (mCRPC). Here, we assessed the antitumor activity and
safety of pembrolizumab in three parallel cohorts of a larger mCRPC population.
METHODS The phase II KEYNOTE-199 study included three cohorts of patients with mCRPC treated with
docetaxel and one or more targeted endocrine therapies. Cohorts 1 and 2 enrolled patients with RECIST-
measurable PD-L1–positive and PD-L1–negative disease, respectively. Cohort 3 enrolled patients with bone-
predominant disease, regardless of PD-L1 expression. All patients received pembrolizumab 200 mg every
3 weeks for up to 35 cycles. The primary end point was objective response rate per RECIST v1.1 assessed by
central review in cohorts 1 and 2. Secondary end points included disease control rate, duration of response,
overall survival (OS), and safety.
RESULTS Two hundred fifty-eight patients were enrolled: 133 in cohort 1, 66 in cohort 2, and 59 in cohort 3.
Objective response rate was 5% (95% CI, 2% to 11%) in cohort 1 and 3% (95% CI,, 1% to 11%) in cohort 2.
Median duration of response was not reached (range, 1.9 to $ 21.8 months) and 10.6 months (range, 4.4 to
16.8 months), respectively. Disease control rate was 10% in cohort 1, 9% in cohort 2, and 22% in cohort 3.
Median OS was 9.5 months in cohort 1, 7.9 months in cohort 2, and 14.1 months in cohort 3. Treatment-related
adverse events occurred in 60% of patients, were of grade 3 to 5 severity in 15%, and led to discontinuation of
treatment in 5%.
CONCLUSION Pembrolizumabmonotherapy shows antitumor activity with an acceptable safety profile in a subset
of patients with RECIST-measurable and bone-predominant mCRPC previously treated with docetaxel and
targeted endocrine therapy. Observed responses seem to be durable, and OS estimates are encouraging.
J Clin Oncol 38:395-405. © 2019 by American Society of Clinical Oncology
INTRODUCTION
In the past decade, therapeutic options for advanced
prostate cancer have increased secondary to im-
proved understanding of the molecular mechanisms
that underlie metastatic progression, including the
critical role of the tumor microenvironment.1 Meta-
static prostate cancer initially responds to androgen
deprivation, the long-standing standard of care. More
recent trials have shown that adding docetaxel2-4 or
abiraterone acetate5,6 to androgen deprivation im-
proves overall survival (OS) in patients with metastatic
hormone-sensitive disease. Eventually, tumors stop
responding to androgen deprivation, a state referred
to as castrate-resistant prostate cancer (CRPC).7 For
patients with metastatic CRPC (mCRPC), treatment
options that confer a survival benefit include docetaxel,8,9
cabazitaxel,10 abiraterone,11,12 enzalutamide,13,14
sipuleucel-T,15 and the bone-specific radionuclide
radium-223.16 These therapies are not curative and
may be associated with poor tolerability.
Monoclonal antibodies that target cytotoxic T-lymphocyte–
associated protein 4, programmed death 1 receptor
(PD-1), and programmed death ligand 1 (PD-L1) have
demonstrated antitumor activity and manageable safety
in several advancedmalignancies. Although checkpoint
inhibition has demonstrated efficacy in urothelial and
renal-cell carcinomas,17-25 prostate cancer has a more
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other genitourinary malignancies,26-28 which suggests that
mCRPC may be less susceptible to immune checkpoint
blockade. The cytotoxic T-lymphocyte–associated protein 4
inhibitor ipilimumab failed to significantly prolong OS in
patients with mCRPC that progressed on docetaxel29 or was
chemotherapy naive.30 Recently, the humanized, anti–PD-1
monoclonal antibody pembrolizumab has demonstrated
antitumor activity and manageable safety in patients with
mCRPC. In 23 patients with PD-L1–positive mCRPC who
were enrolled in KEYNOTE-028, three quarters of whom had
received two or more lines of previous therapy, pem-
brolizumab provided a 17% objective response rate (ORR),
a 30% disease control rate (DCR), and a 37% estimated
12-month OS rate.31 Initial results from the first 10 patients
with enzalutamide-resistant mCRPC who were treated with
pembrolizumab in a phase II study showed a rapid decrease
in prostate-specific antigen (PSA) levels for three patients,
radiographic partial response in two patients, and radio-
graphic stable disease in three patients.32
To further explore the antitumor activity and safety of
pembrolizumab in mCRPC, we performed the KEYNOTE-
199 study. We report results for the first three cohorts,
which enrolled in parallel and included patients who pre-
viously received docetaxel and targeted endocrine therapy
for disease that was measurable and PD-L1 positive (cohort
1) or negative (cohort 2) or that was bone predominant,
regardless of PD-L1 status (cohort 3).
METHODS
Study Design and Patients
KEYNOTE-199 is a five-cohort, open-label, phase II study.
Cohorts 1, 2, and 3 enrolled patients at 85 sites in
21 countries. The trial was conducted in accordance with
Good Clinical Practice and the protocol and its amendments,
which were approved by the appropriate ethics body at each
center. All patients provided written informed consent.
Key eligibility criteria for cohorts 1 to 3 included age
18 years or older; metastatic or locally confined but in-
operable, pathologically confirmed prostate adenocarci-
noma; measurable disease per RECIST v1.133 (cohorts 1
and 2) or detectable bone metastases by whole-body bone
scintigraphy and no RECIST-measurable tumors (cohort 3)
by central review; Eastern Cooperative Oncology Group
performance status 0, 1, or 2; provision of a tumor sample
for PD-L1 assessment (cohort 1 limited to PD-L1–positive
disease, cohort 2 limited to PD-L1–negative disease); and
previous treatment with one or more targeted endocrine
therapies and one to two chemotherapy regimens, one of
which must have included docetaxel. Full inclusion and
exclusion criteria are in the protocol (available in the Data
Supplement).
Treatment
Pembrolizumab 200 mg was administered intravenously
every 3 weeks until disease progression, intolerable toxicity,
physician decision, withdrawal of consent, or a maximum of
35 cycles was reached. Patients with confirmed complete
response who received eight or more pembrolizumab cycles,
including two or more cycles beyond initial complete
response, were permitted to discontinue treatment.
Complete discontinuation criteria and adverse event (AE)
management guidelines are available in the protocol.
Assessments and End Points
PD-L1 expression was assessed at a central laboratory in
formalin-fixed, paraffin-embedded tumor samples using
the PD-L1 IHC 22C3 pharmDx assay (Agilent Technologies,
Carpinteria, CA). Patients in cohorts 1 and 2 were required
to provide biopsy samples from metastatic tumor collected
within 12 months of screening or an archival tumor
specimen if collection from a metastasis was not feasible.
Patients in cohort 3 were required to provide at least an
archival specimen. PD-L1 positivity was defined as a com-
bined positive score (CPS) of$ 1, where CPS is the number
of PD-L1–positive cells—tumor cells, lymphocytes, and
macrophages—divided by the total number of tumor cells 3
100. Mutations in DNA damage repair (DDR) genes were
interrogated using whole-exome sequencing of DNA isolated
from formalin-fixed, paraffin-embedded tumor samples. Com-
plete details are found in the Data Supplement.
Computed tomography, radionuclide bone scanning, and
PSA assessment were performed at baseline, every 9 weeks
during year 1, and every 12 weeks thereafter. AEs were
collected throughout treatment and for 30 days thereafter—
90 days for serious AEs—and graded according to the
National Cancer Institute Common Terminology Criteria for
Adverse Events, version 4.0. Survival was assessed every
12 weeks during follow-up.
The primary end point was ORR per RECIST v1.1,
assessed by central review in patients with measurable
disease at baseline in cohorts 1 and 2 separately and
combined. Secondary end points included DCR per
RECIST v1.1, assessed by central review; ORR, DCR, and
radiographic progression-free survival (rPFS) per Prostate
Cancer Working Group 3 (PCWG3) –modified RECIST
v1.1,34 assessed by central review; PSA response rate,
and OS in cohorts 1 and 2 combined, cohorts 1, 2, and 3
combined, and each cohort separately; duration of re-
sponse per RECIST v1.1 and per PCWG3-modified
RECIST v1.1, assessed by central review for cohorts 1
and 2 combined and separately; and safety and tolerability.
Detailed end point definitions are provided in the Data
Supplement.
Statistical Considerations
The statistical analysis plan is available in the protocol in the
Data Supplement. Antitumor activity and safety were an-
alyzed in all patients who received one or more pem-
brolizumab doses. Patients without a baseline PSA level
were excluded from PSA response analysis. ORR, DCR,
and PSA response rate point estimates and 95% CIs were
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calculated using the Clopper-Pearson exact binomial method.
rPFS, OS, and response duration were estimated using the
Kaplan-Meier method; censoring rules for time-to-event
end points are summarized in the Data Supplement. No
hypothesis testing was planned, and no multiplicity ad-
justments to control for Type I error were performed. The
planned sample size was approximately 200 patients in
cohorts 1 and 2 combined and 50 patients in cohort 3 and
was designed to provide a 95% CI for ORR with an ap-
proximate width of 10%.
RESULTS
Patients
Between July 1, 2016, and March 31, 2017, 260 of 394
patients who were screened for cohorts 1, 2, and 3 were
enrolled (Fig 1). Cohort 1 included 133 patients with
RECIST-measurable, PD-L1–positive disease. Cohort 2
included65patientswithRECIST-measurable, PD-L1–negative
disease and three patients with RECIST-measurable dis-
ease of unknown PD-L1 status. Cohort 3 included 59
patients with bone-predominant disease. Biopsy samples
that were adequate for PD-L1 testing were acquired within
12 months of screening for 122 (92%) of 133 patients in
cohort 1 and 52 (79%) of 66 in cohort 2. These newly
collected samples were from metastases in 98 (80%) of
122 and 48 (92%) of 52 patients, respectively. In cohort 3,
two (9%) of 23 PD-L1–positive and five (14%) of 36
PD-L1–negative samples were acquired within 12 months
of screening; only one newly collected sample, which was
PD-L1 negative, was from a metastasis.
Baseline characteristics were generally as expected for
a docetaxel-treated mCRPC population (Table 1). Across
cohorts, median age was 68 years, 36% of patients had
Eastern Cooperative Oncology Group performance status
0, 29% received two or more previous chemotherapy
regimens, and 25% received two or more previous anti-
androgen therapies. Median PSA level in cohorts 1, 2, and
3 was 115.5 ng/mL, 116.1 ng/mL, and 43.3 ng/mL,
respectively.
As of the August 21, 2018, data cutoff, median follow-up
was 9.5 months in cohort 1, 7.9 months in cohort 2, and
14.1 months in cohort 3, and 4%, 0%, and 3% of patients,
respectively, remained on pembrolizumab (Fig 1). All but
two patients in cohort 2 received one or more pem-
brolizumab doses. The most common reasons for treat-
ment discontinuation were disease progression and AEs.
Median treatment duration was 2.1 months (range, 0.03 to
21.4 months) in cohort 1, 1.6 months (range, 0.03 to 18.7
months) in cohort 2, and 3.2 months (range, 0.7 to 21.9
months) in cohort 3.
Antitumor Activity
Among the 199 patients in cohorts 1 and 2, 29% had
a decrease from baseline in the sum of target lesions, in-
cluding 9% who had a 30% or greater decrease; 26% of
patients had no change or a less than 20% increase in the
sum of target lesions, with similar results in each cohort
(Fig 2A). Considering only the 166 patients with one or
more evaluable postbaseline imaging assessment, 34%
had any decrease, 10% had a 30% or greater decrease,
and 31% had no change or a less than 20% increase in the
sum of target lesions. ORR was 5% (95% CI, 2% to 11%) in
cohort 1, 3% (95% CI, , 1% to 11%) in cohort 2, and 5%
(95% CI, 2% to 8%) in cohorts 1 and 2 combined, per both
RECIST v1.1 and PCWG3-modified RECIST (Table 2). Two
patients, both in cohort 1, achieved a complete radio-
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FIG 1. Patient disposition.
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and both responses in cohort 2 were partial responses
(Appendix Table A1, online only). Per RECIST v1.1, an
additional six patients in cohort 1 and four patients in cohort
2 had stable disease for 6 months or longer leading to
a DCR of 10% and 9%, respectively (Table 2). DCR per
PCWG3-modified RECIST was 13% in cohort 1, 18% in
cohort 2, 39% in cohort 3, 15% in cohorts 1 and 2
combined, and 20% in cohorts 1, 2, and 3 combined
(Table 2). Among the nine patients with radiographic re-
sponse, four remained on treatment at data cutoff, three
had experienced subsequent disease progression, and one
had died without disease progression (Fig 3A). Median
response duration was not reached (range, 1.9 to $ 21.8
months) in cohort 1, was 10.6 months (range, 4.4 to 16.8
months) in cohort 2, and was 16.8 months (range, 1.9 to
$ 21.8 months) in cohorts 1 and 2 combined per both
RECIST v1.1 and PCWG3-modified RECIST.
Median rPFS per PCWG3-modified RECIST was 2.1 months
(95%CI, 2.0 to 2.1months) in cohort 1, 2.1months (95%CI,
2.0 to 3.3 months) in cohort 2, and 3.7 months (95% CI, 2.1
to 4.2 months) in cohort 3 (Fig 3B). Median OS was
9.5 months (95% CI, 6.4 to 11.9 months) in cohort 1,
7.9 months (95% CI, 5.9 to 10.2 months) in cohort 2, and
14.1 months (95% CI, 10.8 to 17.6 months) in cohort 3
(Fig 3C). Estimated 12-month survival rates were 41%, 35%,
and 62%, respectively. In cohorts 1 and 2 combined,median
rPFS was 2.1 months (95% CI, 2.0 to 2.1 months) and
median OS was 8.1 months (95% CI, 6.6 to 10.7 months).
Median rPFS and OS were 2.1 months (95% CI, 2.1 to 2.2
months) and 9.6 months (95% CI, 7.9 to 12.2 months),
respectively, in cohorts 1, 2, and 3 combined.
Of 243 patients in cohorts 1, 2, and 3 with baseline PSA
assessment, 15% experienced some decrease in PSA level,
including 9% who had a 50% or greater decrease and 5%
who had a 90% or greater decrease (Fig 2B). Stable PSA
levels were observed in 9% of patients. Confirmed PSA
responses occurred in 6% of 124 patients in cohort 1, 8%
of 60 in cohort 2, 2% of 59 in cohort 3, 7% of 184 in cohorts
1 and 2 combined, and 6% of 243 in cohorts 1, 2, and 3
combined (Table 2).
Exploratory Biomarker Analysis
Across cohorts, 153 of 258 patients, including six of nine
with complete or partial response, had tumor samples for
TABLE 1. Patient Characteristics at Baseline
Characteristic
Cohort 1 Cohort 2 Cohort 3
PD-L1 Positive PD-L1 Negative Bone Predominant
(n 5 133) (n 5 66) (n 5 59)
Median age, years (range) 68 (48-85) 68 (53-84) 71 (53-90)
ECOG performance status
0 42 (32) 25 (38) 26 (44)
1 75 (56) 36 (55) 27 (46)
2 16 (12) 4 (6) 6 (10)
Missing 0 1 (2) 0
Gleason score
# 7 40 (31) 18 (27) 24 (41)
$ 8 85 (64) 43 (65) 32 (54)
Unknown 8 (6) 5 (8) 3 (5)
Median PSA value, ng/mL (range) 115.5 (0.1-5,000.0) 116.1 (1.0-3,583.0) 43.3 (0.1-2,539.0)
Presence of visceral disease 89 (67) 30 (45) 6 (10)
No. of previous chemotherapy regimens
1 89 (67) 48 (73) 46 (78)
$ 2 44 (33) 18 (27) 13 (22)
Types of previous targeted endocrine therapy
Enzalutamide only 41 (31) 27 (41) 16 (27)
Abiraterone only 57 (43) 24 (36) 28 (47)
Enzalutamide and abiraterone 34 (26) 15 (23) 15 (25)
Other 1 (, 1) 0 0
NOTE. Data are presented as No. (%) unless otherwise indicated.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PD-L1, programmed death-ligand 1; PSA, prostate-specific antigen.
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which whole-exome sequencing was completed. Of these,
19 (12%) had aberrations in BRCA1/2 or ATM and 10 (7%)
had aberrations in one or more of 12 other homologous
recombination repair (HRR) genes (overall prevalence,
19%; Appendix Table A2, online only). None of the six
patients who experienced a response and had evaluable
genomic data were determined to have microsatellite in-
stability as defined by the mSINGS assay.35 ORR per
RECIST v1.1 by central review was 11% in patients with
BRCA1/2 or ATM aberrations, 0% in patients with aber-
rations in one or more of the 12 other HRR genes, and 3%
in patients without any HRR gene aberrations (Appendix
Table A2). Response duration was 4.4 months in the pa-
tient with an ATM mutation and $ 21.8 months in the
patient with a BRCA2mutation. Among the four responders
without aberrations in HRR genes, response duration
ranged from 1.9 months to $ 16.6 months. Dedicated
examination of 50 DDR genes in the six evaluable
objective responders revealed that four patients had so-
matic aberrations in one or more of the genes evaluated
(Appendix Table A3, online only). Local biomarker testing
of two responding patients whose responses lasted more
than 2 years revealed a mismatch repair defect by im-
munohistochemistry that was below the cutoff for high
microsatellite instability by mSINGS with high tumor mu-
tational burden and high CD3 intratumor infiltration in
one patient and an amplified CD274 (PD-L1)/PDCD1LG2
(PD-L2) locus in the other.
Safety
Across cohorts, 155 (60%) patients experienced one or
more treatment-related AEs, including 39 (15%) with one
or more grade 3 to 5 treatment-related AEs and 12 (5%)
who discontinued pembrolizumab because of a treatment-
related AE. Two patients died of AEs that were considered to































































FIG 2. Waterfall plots of change from baseline in tumor size and prostate-specific antigen (PSA) level. (A) Best
percentage change from baseline in the sum of longest diameters of target lesions as assessed by RECIST v1.1 by
central review in the 199 patients enrolled in cohorts 1 and 2. Asterisks represent the 23 patients in cohort 1 and 10
patients in cohort 2 who were not evaluable for change from baseline in tumor size because they did not have one or
more evaluable postbaseline imaging assessment. (B) Best percentage change from baseline in PSA level in the
243 patients enrolled in cohorts 1, 2, and 3 who had a baseline PSA measurement. Asterisks represent the 27
patients in cohort 1, 12 patients in cohort 2, and 11 patients in cohort 3 who had a baseline PSA measurement but
did not have one or more postbaseline PSA measurement. Changes . +100% were truncated at +100%.
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sepsis, n = 1 each). The most common treatment-related
AEs were fatigue, diarrhea, and decreased appetite
(Table 3). The only grade 3 to 5 treatment-related AEs with
an incidence of 1% or greater were colitis and fatigue.
Immune-mediated AEs and infusion reactions, which
were based on a list of terms specified by the sponsor
and considered regardless of attribution to treatment or
immune relatedness by the investigator, occurred in 40
(16%) patients, were grade 3 to 5 in 15 (6%), and led
to discontinuation in four (2%) and death in one patient
(, 1%; the aforementioned pneumonitis). The most com-
mon immune-mediated AEs were colitis, hyperthyroidism,
hypothyroidism, pneumonitis, and severe skin reactions
(n = 6 [2%] each; Table 3).
DISCUSSION
In this multicohort, open-label, phase II study, which to our
knowledge is the largest trial of anti–PD-1 therapy in
mCRPC conducted to date, we showed that pembrolizumab
monotherapy has antitumor activity in patients with mCRPC
previously treated with docetaxel and one or more targeted
endocrine therapies, with approximately 25% of patients
having received both enzalutamide and abiraterone.
Observed OS estimates are promising, suggesting that
immunotherapy may be able to extend the tail of
the survival curve in a historically difficult-to-treat pop-
ulation. Pembrolizumab demonstrated activity in both
RECIST-measurable and bone-predominant disease, as
well as in PD-L1–positive and PD-L1–negative tumors.
Although there was only one PSA response in cohort 3,
rPFS and OS were longer than in cohorts 1 and 2, reflecting
different prognoses of bone-predominant and RECIST-
measurable disease. Pembrolizumab had manageable
safety, and the overall toxicity profile was consistent with
that previously observed for pembrolizumab.
Although the observed ORR was a modest 5%, those
responses that did occur were durable. Among the nine
patients with RECIST-measurable disease who achieved
complete or partial response, five had response ongoing at
data cutoff, and median duration was 16.8 months. The
prolonged response durability is consistent with what has
been previously observed for pembrolizumab in other tumor
types.17,36-39 To capture antitumor activity in bone metas-
tases, which occur in 60% to 70% of men with advanced
prostate cancer,40,41 this study also applied PCWG3-
modified response assessment.34 Whereas ORR and re-
sponse duration in cohorts 1 and 2 were similar regardless of
the criteria applied, DCR was higher in all cohorts using
PCWG3-modified RECIST. These findings highlight the im-
portance of accurately evaluating progression in bone me-
tastases and suggest that PCWG3-modified RECIST may be
preferable for assessing antitumor activity in mCRPC.
This study showed a clear signal of antitumor activity
for pembrolizumab monotherapy in a small number of








Cohorts 1 and 2
Combined
Cohorts 1, 2, and 3
Combined
Response assessed per RECIST
v1.1 by central radiology review
No. of patients 133 66 59 199 258
ORR, No. (%; 95% CI) 7 (5; 2 to 11) 2 (3; , 1 to 11) — 9 (5; 2 to 8) —
DCR,* No. (%; 95% CI) 13 (10; 5 to 16) 6 (9; 3 to 19) 13 (22; 12 to 35) 19 (10; 6 to 15) 32 (12; 9 to 17)
Response assessed per PCWG3-
modified RECIST v1.1 by
central radiology review
No. of patients 133 66 59 199 258
ORR, No. (%; 95% CI) 7 (5; 2 to 11) 2 (3; , 1 to 11) — 9 (5; 2 to 8) —
DCR,* No. (%; 95% CI) 17 (13; 8 to 20) 12 (18; 10 to 30) 23 (39; 27 to 53) 29 (15; 10 to 20) 52 (20; 15 to 26)
PSA response† in patients with
baseline PSA measurement
No. of patients 124 60 59 184 243
Response rate, No. (%; 95% CI) 8 (6; 3 to 12) 5 (8; 3 to 18) 1 (2; 0 to 9) 13 (7; 4 to 12) 14 (6; 3 to 10)
Abbreviations: DCR, disease control rate; ORR, objective response rate; PCWG3, Prostate Cancer Working Group 3; PD-L1, programmed death-ligand 1;
PSA, prostate-specific antigen.
*Defined as the percentage of patients with confirmed complete or partial response of any duration or stable disease or noncomplete response or
nonprogressive disease for 6 months or longer. Patients who died after month 6 without evidence of disease progression before death were considered to have
stable disease for 6 months or longer.
†Defined as the percentage of patients with a reduction in PSA level from baseline by 50% or greater as confirmed on an additional PSA evaluation
performed $ 3 weeks later.
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patients with previously treated mCRPC, which highlights
the importance of identifying predictive biomarkers.42 Ex-
ploratory biomarker analysis did not seem to identify a clear
relationship between response to pembrolizumab and
mutations in DDR genes as determined by whole-exome
sequencing. The contemporaneous presence of mismatch
repair defects could not be excluded, and orthogonal assay
testing beyond next-generation sequencing would be
necessary to determine functional loss. Although there was
no protocol-specified hypothesis testing, outcomes were
similar in patients with PD-L1–positive and –negative
disease using CPS $ 1 to define positivity. Biomarker
analyses were limited by the low number of responses and
the availability of whole-exome sequencing results from
only a fraction of the population. Ongoing and future bio-
marker studies from KEYNOTE-199, including exploration
of different CPS cut points, gene expression profiles, and
tumor mutational burden, will aim to uncover molecular
markers of response to single-agent pembrolizumab.42
Because the mSINGS assay may provide false negatives,
additional assessment of microsatellite instability is also
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FIG 3. Antitumor activity. (A) Swimmer plot of patients with confirmed response as assessed by Prostate Cancer Working Group 3 (PCWG3)–modified
RECIST v1.1 per central review in cohorts 1 (n = 7) and 2 (n = 2) or with stable disease or noncomplete response/nonprogressive disease of 6 or more
months duration in cohorts 1 (n = 10), 2 (n = 10), and 3 (n = 23). Patients who died after month 6 without evidence of disease progression before death were
considered to have stable disease for 6months or longer. The end of the bar indicates the time to the last imaging assessment. (B) Kaplan-Meier estimates of
radiographic progression-free survival (rPFS) as assessed by PCWG3-modified RECIST v1.1 per central review in cohorts 1 (n = 133), 2 (n = 66), and 3 (n =
59). (C) Kaplan-Meier estimates of overall survival (OS) in cohorts 1, 2, and 3.
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the relationship between DNA repair defects of interest and
antitumor activity.
These data add to the growing body of evidence that
suggests that, despite its more immunosuppressive mi-
croenvironment, a small number of select patients with
mCRPC may benefit from pembrolizumab.31,32 Data from
KEYNOTE-199 cohorts 4 and 5 are pending and will help
determine whether pembrolizumab monotherapy has ac-
tivity in patients with RECIST-measurable (cohort 4) and
bone-predominant (cohort 5) chemotherapy-naive mCRPC
receiving ongoing enzalutamide treatment. Initial evidence
of pembrolizumab monotherapy activity has led to several
studies of PD-1 inhibitor-based combination regimens in
mCRPC. Data from themulticohort, phase Ib/II KEYNOTE-365
TABLE 3. Adverse Events Graded According to Common Terminology Criteria for Adverse Events Version 4.0 in the Combined Population of
Cohorts 1, 2, and 3 (N = 258)
Adverse Event Any Grade Grade 3-5*
Treatment-related that occurred in . 5 patients
Fatigue 39 (15) 3 (1)
Diarrhea 28 (11) 2 (, 1)
Decreased appetite 26 (10) 1 (, 1)
Nausea 24 (9) 0
Pruritus 16 (6) 1 (, 1)
Asthenia 15 (6) 0
AST increased 11 (4) 1 (, 1)
Anemia 10 (4) 2 (, 1)
Vomiting 10 (4) 0
Constipation 9 (3) 0
ALT increased 9 (3) 2 (, 1)
Dyspnea 9 (3) 0
Weight decreased 7 (3) 0
Arthralgia 7 (3) 0
Chills 6 (2) 0
Pyrexia 6 (2) 0
Myalgia 6 (2) 0
Rash 6 (2) 0
Immune-mediated and infusion reactions that occurred in $ 1 patient†
Colitis 6 (2) 3 (1)
Hyperthyroidism 6 (2) 0
Hypothyroidism 6 (2) 1 (, 1)
Pneumonitis 6 (2) 1 (, 1)
Severe skin reactions 6 (2) 4 (2)
Infusion reactions 5 (2) 1 (, 1)
Hypophysitis 3 (1) 2 (, 1)
Adrenal insufficiency 2 (, 1) 0
Hepatitis 1 (, 1) 1 (, 1)
Myositis 1 (, 1) 0
Pancreatitis 1 (, 1) 1 (, 1)
Thyroiditis 1 (, 1) 0
Type 1 diabetes mellitus 1 (, 1) 1 (, 1)
NOTE. Data presented as No. (%).
*The only grade 5 treatment-related adverse events were pneumonitis and sepsis in one patient each.
†Immune-mediated adverse events and infusion reactions were adverse events of interest based on an expected immunologic mechanism of
action. The events were based on a list of terms specified by the sponsor and considered regardless of attribution to treatment or immune
relatedness by the investigator. In addition to the preferred terms listed, related terms were also included.
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study demonstrated promising antitumor activity and
manageable safety for combinations of pembrolizumab
with olaparib,44 docetaxel,45 and enzalutamide.46 Data from
the final KEYNOTE-365 cohort of pembrolizumab plus
abiraterone and prednisone are pending (ClinicalTrials.gov
identifier: NCT02861573). Beyond pembrolizumab and
as suggested by an earlier, smaller study,47 the phase II
CheckMate 650 study showed promising antitumor activity
for the combination of nivolumab and ipilimumab in men
withmCRPC, although toxicity was a concern and there was
a suggestion that prior taxane therapy was associated with
lower ORR.48 Several phase III studies of pembrolizumab in
mCRPC that evaluate response on the basis of PCWG3-
modified RECIST are ongoing.
This study has several limitations, including the lack of
randomization, lack of a control arm, and relatively short
follow-up. Because of the inherent biology of metastatic
prostate cancer with its tropism to bone, only a proportion of
patients provided biopsy samples that could be subjected
to whole-exome DNA sequencing. Therefore, the ability to
fully characterize the genetic landscape and identify mo-
lecular markers of response to pembrolizumab was limited.
In conclusion, pembrolizumab monotherapy shows anti-
tumor activity and disease control with an acceptable safety
profile in subsets of patients with RECIST-measurable or
bone-predominant mCRPC previously treated with doce-
taxel and targeted endocrine therapy. Responses seem to
be durable, and the observed OS benefit is encouraging.
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39. Shitara K, Özgüroğlu M, Bang YJ, et al: Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer
(KEYNOTE-061): A randomised, open-label, controlled, phase 3 trial. Lancet 392:123-133, 2018
40. Macedo F, Ladeira K, Pinho F, et al: Bone metastases: An overview. Oncol Rev 11:321, 2017
41. Hernandez RK, Wade SW, Reich A, et al: Incidence of bone metastases in patients with solid tumors: Analysis of oncology electronic medical records in the
United States. BMC Cancer 18:44, 2018
42. Antonarakis ES: A new molecular taxonomy to predict immune checkpoint inhibitor sensitivity in prostate cancer. Oncologist 24:430-432, 2019
43. Rodrigues DN, Rescigno P, Liu D, et al: Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin
Invest 128:5185, 2018
44. Yu EY, Massard C, Retz M, et al: KEYNOTE-365 cohort A: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-
resistant prostate cancer (mCRPC). J Clin Oncol 37, 2019 (suppl 7S; abstr 145)
45. Massard C, Retz M, Hammerer P, et al: KEYNOTE-365 cohort B: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide
(enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC). J Clin Oncol 37, 2019 (supple 7S; abstr 170)
46. Fong PCC, Retz M, Drakaki A, et al: KEYNOTE-365 cohort C: Pembrolizumab (pembro) plus enzalutamide (enza) in abiraterone (abi)-pretreated patients (pts)
with metastatic castrate resistant prostate cancer (mCRPC). J Clin Oncol 37, 2019 (suppl 7S; abstr 171)
47. Boudadi K, Suzman DL, Anagnostou V, et al: Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget
9:28561-28571, 2018
48. Sharma P, Pachynski RK, Narayan V, et al: Initial results from a phase II study of nivolumab (NIVO) plus ipilimumab (IPI) for the treatment of metastatic
castration-resistant prostate cancer (mCRPC; CheckMate 650). J Clin Oncol 37, 2019 (suppl 7S; abstr 142)
n n n
Journal of Clinical Oncology 405
Pembrolizumab for Treatment-Refractory mCRPC
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted.
Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript.
For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/journal/jco/site/ifc.
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).
Emmanuel S. Antonarakis
Honoraria: Sanofi, Dendreon, Medivation, Janssen Biotech, ESSA, Astellas
Pharma, MSD, AstraZeneca, Clovis Oncology
Consulting or Advisory Role: Sanofi, Dendreon, Medivation, Janssen Biotech,
ESSA, Astellas Pharma, MSD, AstraZeneca, Clovis Oncology
Research Funding: Janssen Biotech (Inst), Johnson & Johnson (Inst), Sanofi
(Inst), Dendreon (Inst), Aragon Pharmaceuticals (Inst), Exelixis (Inst),
Millennium Pharmaceuticals (Inst), Genentech (Inst), Novartis (Inst), Astellas
Pharma (Inst), Tokai Pharmaceuticals (Inst), MSD (Inst), AstraZeneca (Inst),
Clovis Oncology (Inst), Constellation Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property: Coinventor of a biomarker
technology licensed to Qiagen
Travel, Accommodations, Expenses: Sanofi, Dendreon, Medivation
Josep M. Piulats
Consulting or Advisory Role: Janssen Oncology, Astellas Pharma, VCN
Biosciences, Clovis Oncology, Genentech, Bristol-Myers Squibb, MSD
Research Funding: Bristol-Myers Squibb, AstraZeneca, MedImmune, MSD,
Pfizer, EMD Serono, Incyte, Janssen Oncology
Travel, Accommodations, Expenses: Janssen Oncology, Roche, Bristol-Myers
Squibb
Marine Gross-Goupil
Honoraria: Ipsen, Janssen-Cilag, Sanofi
Consulting or Advisory Role: Bristol-Myers Squibb, MSD, Pfizer, Ipsen, Roche
Research Funding: Pfizer, MSD, Roche, Ipsen, Janssen-Cilag
Travel, Accommodations, Expenses: Amgen, Roche, Ipsen, MSD
Jeffrey Goh
Stock and Other Ownership Interests: Immutep
Research Funding: MSD (Inst)
Consulting or Advisory Role: Tesaro, AstraZeneca
Speakers’ Bureau: Novartis, Ipsen, Jansen, Mundipharma
Travel, Accommodations, Expenses: Astellas Pharma, AstraZeneca
Kristiina Ojamaa
Consulting or Advisory Role: AstraZeneca
Research Funding: MSD (Inst)
Christopher J. Hoimes
Honoraria: Seattle Genetics
Consulting or Advisory Role: Foundation Medicine, Bristol-Myers Squibb, Eisai,
Prometheus Laboratories, Seattle Genetics, Genentech, MSD, 2bPrecise
Speakers’ Bureau: Bristol-Myers Squibb, Genentech
Research Funding: MSD, MSD (Inst)
Ulka Vaishampayan
Honoraria: Pfizer, Bayer, Sanofi, Bristol-Myers Squibb, Exelixis
Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, Exelixis, Bayer, EMD
Serono
Speakers’ Bureau: Pfizer, Bayer, Bristol-Myers Squibb, Exelixis, Sanofi, Eisai
Research Funding: Astellas Pharma, Exelixis, Pfizer, Bristol-Myers Squibb, MSD
(Inst)
Raanan Berger
Stock and Other Ownership Interests: Mitra Biotech, Belong
Honoraria: Mitra Biotech, Bristol-Myers Squibb, Roche, AstraZeneca, Pfizer,
MSD Oncology
Consulting or Advisory Role:Mitra Biotech, Belong, MSD, Bristol-Myers Squibb
Research Funding: MSD (Inst)
Speakers’ Bureau: Mitra Biotech, Bristol-Myers Squibb, MSD
Travel, Accommodations, Expenses:Mitra Biotech, Bristol-Myers Squibb, MSD,
AstraZeneca
Ahmet Sezer
Honoraria: Pfizer (Inst), Roche (Inst), Amgen (Inst)
Speakers’ Bureau: Roche, Pfizer, Amgen, Bristol-Myers Squibb
Research Funding: Regeneron (Inst), MSD (Inst), Pfizer (Inst), Novartis (Inst),
Merck Serono (Inst), Novartis (Inst)
Travel, Accommodations, Expenses: Amgen, Bristol-Myers Squibb, Roche
Tuomo Alanko
Consulting or Advisory Role: Amgen, Bayer, Baxalta, Shire, Bristol-Myers
Squibb, Celgene, Eli Lilly, MSD, Netmedi, Nordic Drugs, Roche
Research Funding: AbbVie (Inst), Bayer (Inst), Boehringer Ingelheim (Inst),
Bristol-Myers Squibb (Inst), Eli Lilly (Inst), Incyte (Inst), MSD (Inst), Pfizer (Inst),
Roche (Inst)




Consulting or Advisory Role: Sanofi, MSD, Genentech, Janssen, Bayer, Clovis
Research Funding: Sanofi (Inst), Bayer (Inst), MSD (Inst)
Travel, Accommodations, Expenses: Eli Lilly
Chunde Li
Stock and Other Ownership Interests: Chundsell Medicals
Research Funding: MSD (Inst)
Patents, Royalties, Other Intellectual Property: Royalty agreement with
Chundsell Medicals on the basis of a patent granted in Sweden and pending for
grant internationally
Aurelius Omlin
Consulting or Advisory Role: Astellas Pharma (Inst), Bayer (Inst), Sanofi (Inst),
Roche (Inst), Janssen (Inst), MSD (Inst), Molecular Partners (Inst)
Research Funding: Teva (Inst), Janssen (Inst), MSD (Inst)
Travel, Accommodations, Expenses: Sanofi, Bayer, Astellas Pharma, Janssen
Giuseppe Procopio
Consulting or Advisory Role: Bayer, Bristol-Myers Squibb, Janssen, Novartis,
Astellas Pharma, Pfizer, Ipsen, MSD
Research Funding: MSD (Inst)
Satoshi Fukasawa
Honoraria: Ono Pharmaceutical, Bristol-Myers Squibb, MSD, Astellas Pharma,
AstraZeneca, Novartis, Pfizer, Janssen, Takeda, Daiichi Sankyo
Consulting or Advisory Role: AstraZeneca
Research Funding: MSD (Inst)
Se Hoon Park
Consulting or Advisory Role: Eli Lilly
Research Funding: MSD (Inst)
Susan Feyerabend
Research Funding: MSD (Inst)
Consulting or Advisory Role: Janssen-Cilag, Astellas Pharma
Charles G. Drake
Stock and Other Ownership Interests: Compugen, Tizona Therapeutics,
Harpoon Therapeutics, Kleo Pharmaceuticals
Consulting or Advisory Role: AstraZeneca, MedImmune, Bristol-Myers Squibb,
Compugen, Genentech, Janssen Oncology, Pfizer, Tizona Therapeutics,
Potenza Therapeutics, MSD, Pierre Fabre
Research Funding: Bristol-Myers Squibb (Inst), MSD (Inst)
Patents, Royalties, Other Intellectual Property: Patents licensed to Bristol-
Myers Squibb (Inst), Patents licensed to Potenza Therapeutics (Inst)
Travel, Accommodations, Expenses: Genentech, American Association for
Cancer Research, American Society of Clinical Oncology, MSD, Pfizer
Haiyan Wu
Employment: MSD
Stock and Other Ownership Interests: MSD (I)
Ping Qiu
Employment: MSD
Stock and Other Ownership Interests: MSD
Jeri Kim
Employment: MSD




Stock and Other Ownership Interests: MSD
© 2019 by American Society of Clinical Oncology Volume 38, Issue 5
Antonarakis et al
Johann Sebastian de Bono
Honoraria: AstraZeneca, Sanofi, Astellas Pharma, Pfizer, Genentech, Janssen
Oncology, Menarini Silicon Biosystems, Daiichi Sankyo, Sierra Oncology,
Bioexcell
Consulting or Advisory Role: AstraZeneca, Sanofi, Genentech, Astellas Pharma,
Bayer, Pfizer, Merck Sharp & Dohme, Merck Serono, Boehringer Ingelheim,
Sierra Oncology, Menarini Silicon Biosystems, Celgene, Taiho Pharmaceutical,
Daiichi Sankyo, Janssen Oncology, Genmab, GlaxoSmithKline, Orion Pharma,
Eisai, BioXCel Therapeutics
Research Funding: AstraZeneca (Inst), Genentech (Inst), Sanofi (Inst), Taiho
Pharmaceutical (Inst), Daiichi Sankyo (Inst), Merck Serono (Inst), Astex
Pharmaceuticals (Inst), Merck Sharp & Dohme (Inst), Orion Pharma (Inst),
GlaxoSmithKline (Inst), CellCentric (Inst), Celgene (Inst), Sierra Oncology (Inst),
Bayer (Inst), MedImmune (Inst), Medivation (Inst)
Patents, Royalties, Other Intellectual Property: Abiraterone rewards to
inventors (Inst), PARP inhibitors and DNA repair defects (Inst), Targeting of
IL-23 in prostate cancer (Inst), CHK1 inhibitor (Inst)
Travel, Accommodations, Expenses: AstraZeneca, Astellas Pharma,
GlaxoSmithKline, Orion Pharma, Sanofi, Genmab, Taiho Pharmaceutical,
Qiagen, Vertex
No other potential conflicts of interest were reported.
Journal of Clinical Oncology
Pembrolizumab for Treatment-Refractory mCRPC
APPENDIX Pembrolizumab for Treatment-Refractory Metastatic
Castration-Resistant Prostate Cancer: Multicohort, Open-
Label Phase II KEYNOTE-199 Study
Emmanuel S. Antonarakis, Josep M. Piulats, Marine Gross-Goupil,
Jeffrey Goh, Kristiina Ojamaa, Christopher J. Hoimes, Ulka Vaish-
ampayan, Ranaan Berger, Ahmet Sezer, Tuomo Alanko, Ronald
de Wit, Chunde Li, Aurelius Omlin, Giuseppe Procopio, Satoshi
Fukasawa, Ken-ichi Tabata, Se Hoon Park, Susan Feyerabend,
Charles G. Drake, Haiyan Wu, Ping Qiu, Jeri Kim, Christian Poehlein,
Johann Sebastian de Bono
METHODS
Whole-Exome DNA Sequencing. Whole-exome DNA sequences
were aligned to reference human genome GRCh37 (Burrows-Wheeler
Aligner), variants were detected using GATK, and somatic single-
nucleotide variants were called using MuTect. DNA damage repair
genes examined were ATM, ATR, BAP1, BARD1, BLM, BRAP,
BRCA1, BRCA2, BRIP1, CDH1, CDK12, CENPQ, CHEK1, CHEK2,
EPCAM1, ERCC1, ERCC2, ERCC3, ERCC4, ERCC6, FAM175A,
FAM175B, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG,
FANCI, FANCL, GEN1, HDAC2, MLH1, MLH3, MRE11A, MSH2,
MSH6, MUTYH, NBN, PALB2, PIF1, PMS2, RAD51, RAD51B,
RAD51C, RAD51D, RAD54L, RDM1, TP53, and XRCC2. Pathogenic
or likely pathogenic mutations were defined as those that were
predicted to result in protein loss—homozygous deletions—or pro-
tein truncation—nonsense mutations, frameshift insertions or de-
letions, and splicing mutations at conserved splice donor/acceptor
sites—except in the case of TP53, where known inactivation mis-
sense mutations were also coded as pathogenic. Sequence alter-
ations not known to alter the encoded protein were denoted as
variants of unknown significance.
Definitions of Study End Points and Censoring Rules for Time-
to-Event End Points. Objective response rate was defined as the
percentage of patients with confirmed complete or partial response.
Disease control rate was defined as the percentage of patients with
best overall response of stable disease for 6 months or longer or
confirmed complete or partial response. Radiographic progression-
free survival was defined as the time from the first day of study
treatment to disease progression or death from any cause, whichever
occurred first; data for patients who were alive and did not experience
disease progression were censored at the time of last tumor assess-
ment. Overall survival was defined as the time from the first day of study
treatment to death from any cause; data for patients who were alive
were censored at the time of last contact. The prostate-specific antigen
response rate was defined as the percentage of patients with a 50% or
greater reduction in the prostate-specific antigen level from baseline
confirmed on an evaluation performed 3 weeks later or longer. Du-
ration of response was defined as the time from first documented
evidence of complete or partial response until progressive disease or
death as a result of any cause, whichever occurred first, in patients with
confirmed complete or partial response.
Censoring rules for duration of response were as follows:
• Data for responders who were alive and without disease
progression or new anticancer therapy were censored at the
time of last tumor assessment.
• Data for responders who were alive and without disease
progression but who started new anticancer therapy were
censored at the time of last tumor assessment before the start
of the new anticancer therapy.
• Data for responders who died or had disease progression after
two or more missed adequate tumor assessments were
censored at the time of last adequate tumor assessment
before the two or more missed adequate tumor assessments.
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TABLE A1. Summary of Best Overall Response in Cohorts 1, 2, and 3
Response
Cohort 1 (PD-L1 positive;
n = 133)
Cohort 2 (PD-L1 negative;
n = 66)
Cohort 3 (bone predominant;
n = 59)
Response assessed per RECIST v1.1 by
central radiology review
Complete response 2 (2) 0 —
Partial response 5 (4) 2 (3) —
Stable disease of any duration 23 (17) 14 (21) —
$ 6-mo duration 6 (5) 4 (6) —
Non-CR/non-PD* of any duration 0 0 22 (37)
$ 6-mo duration 0 0 13 (22)
Progressive disease 79 (59) 42 (64) 32 (54)
Not evaluable† 4 (3) 1 (2) 1 (2)
Not assessable‡ 20 (15) 7 (11) 4 (7)
Response assessed per PCWG3-modified
RECIST v1.1 by central radiology review
Complete response 2 (2) 0 0
Partial response 5 (4) 2 (3) 0
Stable disease of any duration 29 (22) 25 (38) 0
$ 6-mo duration 10 (8) 10 (15) 0
Non-CR/non-PD* of any duration 0 0 35 (59)
$ 6-mo duration 0 0 23 (39)
Progressive disease 71 (53) 30 (45) 19 (32)
Not evaluable† 6 (5) 2 (3) 1 (2)
Not assessable‡ 20 (15) 7 (11) 4 (7)
NOTE. Data presented as No. (%).
Abbreviations: CR, complete response; PCWG3, Prostate Cancer Working Group 3; PD, progressive disease; PD-L1, programmed cell death ligand 1.
*Patients without disappearance of all existing lesions or development of new lesions.
†Patients who had one or more postbaseline imaging assessment, none of which were evaluable for response.
‡Patients who did not undergo postbaseline imaging.
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TABLE A3. Genomic Analysis of 50 DNA Damage Repair Genes in the Six Responders With Evaluable Whole-Exome Sequencing Data
Patient 1 (cohort 1) Patient 2 (cohort 1) Patient 3 (cohort 2) Patient 4 (cohort 1) Patient 5 (cohort 1) Patient 6 (cohort 1)


















NOTE. The following 50 DNA damage repair genes were examined: ATM, ATR, BAP1, BARD1, BLM, BRAP, BRCA1, BRCA2, BRIP1, CDH1, CDK12,
CENPQ, CHEK1, CHEK2, EPCAM1, ERCC1, ERCC2, ERCC3, ERCC4, ERCC6, FAM175A, FAM175B, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG,
FANCI, FANCL, GEN1, HDAC2, MLH1, MLH3, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PIF1, PMS2, RAD51, RAD51B, RAD51C, RAD51D,
RAD54L, RDM1, TP53, and XRCC2.
†Variants of unknown significance.
TABLE A2. Tumor and PSA Response by Presence of Monoallelic and Biallelic Aberrations in BRCA1/2, ATM, or Other HRR Genes as Assessed by
Whole-Exome Sequencing in Evaluable Patients in Cohorts 1, 2, and 3 Combined
Variable
BRCA1/2 or ATM Aberrant
(n = 19)
Aberrations in Other HRR Genes*
(n = 10)
No Aberrations in HRR Genes
(n = 124)
RECIST v1.1, central review
ORR 2 (11)† 0 4 (3)
DCR (any duration) 4 (22) 0 22 (18)
Best response
CR 0 0 2 (2)
PR 2 (11) 0 2 (2)
SD (any duration) 2 (11) 2 (20) 18 (15)
Non-CR/non-PD 1 (5) 0 7 (6)
PD 12 (63) 5 (50) 80 (65)
NE or missing 2 (11) 3 (30) 15 (12)
PSA response 2 (11) 1 (10) 4 (3)
NOTE. Data presented as No. (%).
Abbreviations: CR, complete response; DCR, disease control rate; HRR, homologous recombination repair; NE, not evaluable; ORR, objective response
rate; PD, progressive disease; PR, partial response; PSA, prostate-specific antigen; SD, stable disease.
*BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51C, RAD51B, RAD51D, and RAD54L.
†One patient each from cohorts 1 and 2.
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